MOH Leads Peers in Both Price and Call-Side Repositioning

Molina Healthcare outpaced its closest managed-care peers on the week, gaining 4.9% to close at $219.72 while the peer median landed around 3.2%, with UNH the outlier at nearly 11% and CNC and ELV both adding 2.8% to 3.5%.

The most striking repositioning happened in options. Call buyers have taken clear control: the put/call ratio dropped to 0.80 on October 20, its lowest reading of the past 52 weeks and 3.3 standard deviations below its 20-day average of 1.18. For most of September and into early October, the ratio traded in a tight band around 1.24. The break lower began on October 19 at 0.89 and extended the following day. That is not a gradual drift; it is an abrupt rotation away from the defensive hedging posture that had dominated for six consecutive weeks. Utilization has moved in the same direction, easing from above 1.3% in early October to just 0.44% by October 20, the lightest level of the past 30 days, and availability in the lending pool remains at the practical ceiling with roughly 100 shares available for every one currently borrowed.

Short interest reinforces the same picture. Bears have been reducing exposure steadily. The short position is now 5.5% of the free float, down from roughly 6.3% a month ago, an 8.3% one-month decline. The most notable step-down came in the first week of October, when positions fell from around 3.2 million shares to 2.84 million in just a few sessions. Cost to borrow remains low at 0.46%, and with availability this deep, there is no mechanical friction pressing existing shorts to cover. The reduction looks voluntary rather than forced, which matters: shorts are leaving of their own accord as the stock recovers, not being squeezed out.

The Street is less enthusiastic. The analyst consensus is a hold, with 15 hold ratings and no outperform on record. Targets were marked down uniformly after the July earnings release, with Wells Fargo cutting to $220, RBC to $218, and Truist to $225, all from levels in the $235 to $250 range. The Barclays underweight target sits at $180, well below where the stock trades today. EPS momentum tells a different story: the 90-day reading ranks in the 91st percentile and the 12-month forward EPS year-on-year growth estimate ranks in the 98th percentile. The bear case is real, centred on a Medicaid rate environment modelling 4% against roughly 5% cost trend, OBBBA-related membership attrition potentially above 6%, and the 2029 EPS backlog revised down from above $11 to $9 per share. The bull case rests on the Duals opportunity, where Molina has only 6% penetration in markets where it holds 16% Medicaid share, and a management framework pointing toward $64 billion in premium revenue by 2029. The stock's EV/EBITDA of 11.8x has expanded by about 0.24x over the past month, modest multiple expansion that is consistent with the price recovery but not a re-rating.

Earnings arrived on October 22, and the prior two prints set a clear pattern: the stock fell roughly 11% the day after each of the last two releases, with five-day losses extending to 12%. The October print, now the live variable, is the level to watch. A reaction that diverges materially from that pattern, in either direction, would be the most informative data point for whether the call-buying rotation of the past two sessions reflected genuine optimism or simply pre-earnings positioning being unwound.